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Abstract
Background:  Quantitative Polymerase Chain Reaction (qPCR) is a well-established method for
quantifying levels of gene expression, but has not been routinely applied to the detection of constitutional
copy number alterations of human genomic DNA. Microdeletions or microduplications of the human
genome are associated with a variety of genetic disorders. Although, clinical laboratories routinely use
fluorescence in situ hybridization (FISH) to identify such cryptic genomic alterations, there remains a
significant number of individuals in which constitutional genomic imbalance is suspected, based on clinical
parameters, but cannot be readily detected using current cytogenetic techniques.
Results: In this study, a novel application for real-time qPCR is presented that can be used to reproducibly
detect chromosomal microdeletions and microduplications. This approach was applied to DNA from a
series of patient samples and controls to validate genomic copy number alteration at cytoband 22q11. The
study group comprised 12 patients with clinical symptoms of chromosome 22q11 deletion syndrome
(22q11DS), 1 patient trisomic for 22q11 and 4 normal controls. 6 of the patients (group 1) had known
hemizygous deletions, as detected by standard diagnostic FISH, whilst the remaining 6 patients (group 2)
were classified as 22q11DS negative using the clinical FISH assay. Screening of the patients and controls
with a set of 10 real time qPCR primers, spanning the 22q11.2-deleted region and flanking sequence,
confirmed the FISH assay results for all patients with 100% concordance. Moreover, this qPCR enabled a
refinement of the region of deletion at 22q11. Analysis of DNA from chromosome 22 trisomic sample
demonstrated genomic duplication within 22q11.
Conclusion: In this paper we present a qPCR approach for the detection of chromosomal microdeletions
and microduplications. The strategic use of in silico modelling for qPCR primer design to avoid regions of
repetitive DNA, whilst providing a level of genomic resolution greater than standard cytogenetic assays.
The implementation of qPCR detection in clinical laboratories will address the need to replace complex,
expensive and time consuming FISH screening to detect genomic microdeletions or duplications of clinical
importance.
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Background
Array comparative genomic [1-3] and FISH-based meth-
ods [4] have been widely used for the detection of DNA
copy number changes. However, the resolution of com-
mercially available DNA arrays can be too low to detect
microdeletions or microduplications [5,6], whilst FISH is
generally only useful when the regions of interest have
been previously defined. Currently, DNA arrays providing
full coverage of the human genome are not widely availa-
ble and too expensive to diagnostically screen large num-
bers of patients. Moreover, the findings that are emerging
from recent array comparative genomic hybridization
studies indicate that significant validations of both con-
trols and patient populations will be required to make
phenotype-genotype interpretations in a clinical context.
Similarly, standard FISH methods are time consuming,
costly and suffer the significant limitation that some
patients with uniquely localized microdeletions or dupli-
cations may yield normal clinical FISH findings because
the probe set used does not map precisely to the entire
region of deletions/duplication.
In this study we have chosen to validate the use of qPCR
technology for detection of microdeletions or microdupli-
cations using Velocardiofacial Syndrome (VCFS) or chro-
mosome 22q11 deletion syndrome (22q11DS) as a test
model. The frequency of the causative deletion for
22q11DS in the general population is 1 in 3000 live
births, making it one of the most common constitutional
genomic alterations found in humans [7]. 22q11DS is
suspected in individuals with characteristic clinical find-
ings and is confirmed in most cases by detection of a sub-
microscopic deletion using FISH.
The currently accepted clinical laboratory assay for
22q11DS uses the TUPLE1 FISH probe, which is located
within a typically deleted region of approximately 3 Mb.
Schematics of the 22q11.2 region Figure 1
Schematics of the 22q11.2 region. Previously reported deletions and deletions identified from our study are shown. A) 
The 10 qPCR primers used to screen for hemizygous deletions, orientation is centromere to telomere. B) Known low copy 
number repeats or segmental duplications in 22q11.2: LCR-A, LCR-B and LCR-D (Shaikh et al., 2000). C) Known genes [24]. 
D) Location of previously reported deletions in 22q11DS patients. E) Locations of hemizygous deletions and duplications iden-
tified in this study. For D and E, hashed ends represent regions of uncertainty regarding precise location of deletion break-
points.B
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Table 1: Sequence and parameters of the reference and 22q11.2 test primer sets. Ten sets of primers were designed from within regions of unique sequence on 22q11.2 using 
Primer Express v2.0. In addition, two sets of reference primer for G6PDH and HEM3 were also designed to allow for data correction.
Primer Sets No. Primer Name Primer Sequence Chr. Genomic Location
of Amplicon
Amplicon
Size (bp)
Cycle
Treshold
Slope R2
Reference 1 G6PDH-F TCTTCATCACCACAGAGAACTTGC 1 9033513–9033733 221 0.2 -3.2968 0.9980
G6PDH-R GACCTGGAAGTCACTGGGCA
2 HEM3-F TGCACGGCAGCTTAACGAT 11 118501618–118501818 202 0.2 -3.3998 0.9981
HEM3-R AGGCAAGGCAGTCATCAAGG
Test 1 D22S181-F CAGCTCCCAAGTCTTTCCAGC 22 16968759–16968859 101 0.2 -3.4141 0.9986
D22S182-R CCAGGGTAGGAAACAGGTCGA
2 PRODH-F GGGAAAGGAGAGTTCAGGCAG 22 17293217–17293317 101 0.2 -3.5102 0.9992
PRODH-R GCTTGTTGAATAGCCTCTGTCCTAG
3 TUPLE1-F GGCAAGTGCAATATTCATGTGGT 22 17763150–17763250 101 0.2 -3.2564 0.9996
TUPLE1-R TCCTACACGCCTGACAAAGCT
4 COMT-F GTGCTACTGGCTGACAACGTGAT 22 18330640–18330739 100 0.2 -3.5876 0.9928
COMT-R GGAACGATTGGTAGTGTGTGCA
5 ZNF74-F TGGCCTCCTGCTTCTTTCTTC 22 19073892–19073992 101 0.2 -3.2263 0.9960
ZNF74-R CAGACACTCCAATTCATGACGAA
6 PIK4CA-F ATGCTTGTGCGACGCAGAC 22 19429805–19429905 101 0.06 -3.0238 0.9958
PIK4CA-R CCTCAGCCATGTTGACTCAGC
7 LZTR1-F TCATCATGGATGTGTACAAACTGG 22 19673422–19673524 103 0.2 -3.2416 0.9977
LZTR1-R AGCACGTTCTGCAGGTCCAC
8 CAT4-F TACCTGGGCTTCTTGGATGG 22 19708684–19708784 101 0.2 -3.4394 0.9986
CAT4-R AAGACAAGCACGCAGCCTATG
9 D22S936-F TGGCAGCCAGTTTAGTATTCTGC 22 19777314–19777414 101 0.2 -3.1972 0.9960
D22S936-R TTGTAATCAAGTCCCGCCACT
10 VPREB1-F CGACCATGACATCGGTGTGT 22 20924000–20924102 103 0.2 -3.2923 0.9972
VPREB1-R CTGGCTCTTGTCTGATTGTGAGABMC Genomics 2005, 6:180 http://www.biomedcentral.com/1471-2164/6/180
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Although this assay can detect the majority of affected
patients (85–90%), many patients with phenotypic fea-
tures of 22q11DS have no deletion detectable by FISH
testing. As a consequence these patients will go undiag-
nosed due to the presence of atypical deletions that map
outside the area covered by the TUPLE1 probe [8-12]. In
addition, there have been reports of individuals with
some features of 22q11DS with microduplications of
22q11.2 [13]. Unfortunately, clinical FISH assays are not
usually capable of detecting such duplications, so alterna-
tive methods, such as FISH analysis of interphase nuclei,
are required [14]. However, such techniques require
advanced optical instrumentation, presently only used in
specialized research laboratories. Alternative molecular
technologies that could potentially be used to screen dele-
tions in the diagnose of 22q11DS is multiplex ligation-
dependent probe amplification (MLPA) [15] or microsat-
ellites marker analysis [10].
The novel approach validated in this study utilized qPCR
rather than FISH to detect copy number alterations
(microdeletions and microduplications) in patient DNA.
This approach had several advantages. Primers were
selected within regions of unique sequence utilizing pub-
licly available sequence databases [16-24]. This method
can allow for the production of a high-resolution map of
any region of interest; the 22q11DS region is used in this
example. The qPCR technique provides a quantitative
measurement of DNA copy number and accurately char-
acterizing chromosomal breakpoints. This method will
therefore permit the identification of individuals who
would otherwise go undetected by the currently available
clinical FISH methods. In addition, qPCR provides greater
flexibility and adaptability, whilst being less technically
challenging than FISH, thus making it more appropriate
for use in a large number of laboratories. Furthermore, the
qPCR technique only takes a fraction of the time usually
required for FISH, which allows for multiple samples and
multiple primer sets to be studied in parallel, using con-
venient and cost effective high throughput analysis. The
method described in this paper has been evaluated using
patient and controls samples with known copy number
changes on 22q11. The approach can be readily adapted
for molecular diagnostics of any region of the genome suf-
fering recurrent constitutional genomic deletion or dupli-
cation.
Results
Fish results
The twelve patients utilized in this study have previously
been analysed in a clinical laboratory by FISH using the
TUPLE 1 probe. Using this test, six of the patients (group
1) were identified as 22q11 deletion positive whilst the
other six (group 2) and the four controls showed normal
cytogenetic results. The DNA sample known to have three
copies of 22q11 (trisomy for chromosome 22) had been
previously analysed by FISH [25].
Primer design
The most critical factor for successful detection of micro-
alterations using qPCR was primer design. To guarantee
optimal primer design a high-resolution 22q11.2 physical
map was constructed using information available from
published reports [8-12,26-34] and online databases and
repositories [16-24]. This allowed for the identification of
unique sequences within the 22q11DS affected region
whilst also avoiding the complex repetitive regions. Figure
1 shows a schematic representation of the 22q11.2 region
studied in this work, the location of previously reported
deletions and deletions identified from our study are
shown as are the location of primers, repeat sequences,
known genes and pseudogenes.
Sequences were selected to lie, mostly, within exonic and/
or intervening regions from known or putative genes:
UniSTS marker D22S181 (UniSTS is a comprehensive
database of sequence tagged sites) [35], Proline Dehydro-
genase/Proline Oxidase (PRODH), TUP-like enhancer of
SPLIT 1 (TUPLE1), Catechol-O-Methyltransferase
(COMT), Zinc Finger Protein 74 (ZNF74), Phosphatidyli-
nositol 4-kinase (PIK4CA), Leucine-zipper-like Transcrip-
tional Regulator 1 (LZTR1), Cationic Amino acid
Transporter-4 (CAT4), D22S936 and Similar to Pre-B lym-
phocyte gene 1 (VPREB1). The selected sequences were
aligned against the human genome using the BLAT pro-
gram [36] to ensure that only contiguous sequences with
100% homology to one unique location were selected. A
single primer set was then designed from each of these
unique sequences using the Primer Express v 2.0 program
(Applied Biosystems). We designed reference primers for
each of the "housekeeping genes" Glucose-6-Phosphate
Dehydrogenase (G6PDH) and Hydroxymethylbilane Syn-
thase (HEM3) which were selected using published guide-
lines [37]; moreover we insured that they were single copy
genomic sequences according to the BLAT alignment [38],
in addition agarose gel visualization confirmed a single
band of the expected size. All primer sequences are shown
in Table 1. The use of reference primers was to control for
varying input amounts of DNA from each separate
patient. Thus any differences in the qPCR values obtained
for test primers/markers would correspond to differences
in the amount of the primers target sequence.
Optimization process
Primer concentrations were optimised over a range of
final concentrations, 100 nM to 900 nM at 100 nM inter-
vals. The optimal concentration was that which obtained
the lowest threshold cycle (Ct) and maximum ∆Rn while
minimizing non-specific amplification. The results indi-
cated that for all of the 22q11.2 primer sets the optimalBMC Genomics 2005, 6:180 http://www.biomedcentral.com/1471-2164/6/180
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final primer concentration was 800 nM, whilst for the
G6PDH and HEM3 primer sets this value was 400 nM.
The specificity of amplification for each qPCR product
was confirmed by determining that the melting curve,
showed a single dissociation peak corresponding to the
melting temperature of the analysed amplicons (See Addi-
tional File 3, Figure 2 b. Dissociation Curve for PRODH -
14 DNA samples).
To allow for comparisons between each primer sets all
had to amplify with comparable efficiency. This was
assessed by analysis of the slopes from the standard
curves, which were generated using a log10 dilution series
of input genomic DNA (range 102 nM to 10-2 nM). If all
conditions are optimal and reactions are 100% efficient, it
will take approximately 3.32 cycles for ten fold amplifica-
tion (log2 of 10 = 3.321928) of product, a value that is
equal to the slope of the standard curve. This translates to
1 cycle to copy 1 molecule into 2; a second cycle to copy
2 molecules into 4; a third cycle to copy 4 into 8 and 0.32
cycles to copy 8 into 10. There was a linear relationship
between the amount of input DNA and the threshold
cycle (Ct) values for the various reactions. Regression anal-
yses of the Ct values generated by the log10 dilution series
gave R2 values for all reactions in excess of 0.99 (Table 1).
At the optimal primer concentrations all of the primer sets
gave slope values of 3.32 ± 0.25, indicating that the reac-
tions were occurring with similar efficiencies. Following
primer optimisation a baseline Ct was identified for each
primer set, which was used when analysing subsequent
data (R2, slope and threshold cycle values are shown in
Table 1).
Data correction/normalization
To control for differences in sampling, DNA preparation,
reaction efficiency (the varying PCR efficiencies between
patient samples and the calibrator) [39] and other varia-
bles such as the Ct values for each primer pair [40] from
22q11.2 were corrected/normalized using the Ct value of
the G6PDH and HEM3 products for the same sample.
Although the input of template was standardised at 10 ng
of DNA, the Ct values for the housekeeping genes differed
slightly from patient to patient and from group to group
(Table 3), thus demonstrating the need for correction of
the raw data prior to further analysis.
Correction was performed using a method described by
Moody et al. (2000) [41]. Once the corrected Ct values
(KCt) for each of the test markers had been determined it
was then possible to identify fold copy number change
Table 2: Fold copy number change (∆KCt) for the 12 22q11DS patients, 22q11 Duplication and 4 controls. ∆KCt values of 0 ± 0.35 
indicate an equal ratio of the target and reference, which corresponds to no loss and therefore no genetic abnormality, values of -1 ± 
0.35 indicate loss of one copy (microdeletion), whilst values of 1 ± 0.35 (seen for the trisomy 22 patient) indicate gain of one copy 
(microduplication).
Sample Types Samples qPCR Primers of the 22q11.2 DS Region
D22S181 PRODH TUPLE1 COMT ZNF74 PIK4 LZTR1 CAT4 D22S936 VPREB1
Fold copy number change (∆KCt)
Normal Controls 1 -0.1601 0.2039 0.1716 0.1273 0.0744 0.1097 -0.1598 0.0175 -0.2195 0.1782
2 0.0881 -0.0115 -0.0703 -0.0045 -0.0744 -0.1421 0.0538 -0.1002 -0.0327 0.1738
3 -0.0802 -0.1322 -0.0202 0.0471 0.1633 0.0211 0.1497 -0.1193 0.1580 -0.1393
4 -0.2727 -0.0602 -0.0812 -0.1700 0.2048 0.0113 -0.2035 -0.1173 -0.1508 -0.2128
22q11DS Tuple1 
Deleted
1 -0.2006 -1.2337 -1.2173 -0.9261 -1.2366 -1.1903 -0.9009 -1.1467 -1.1305 0.0140
2 0.1987 -1.1857 -1.2806 -1.1102 -0.8132 -0.9187 -1.2182 -0.8644 -1.1021 -0.0667
3 -0.0035 -1.2003 -1.1671 -1.2660 -1.0857 -1.2183 -0.8808 -1.1124 -1.3388 -0.3315
4 -0.0387 -1.2372 -1.2534 -1.2976 -0.9337 -1.1139 -1.1951 -0.9513 -0.9711 0.0759
5 -0.2601 -0.9173 -1.1538 -0.9330 -0.9639 -0.9715 -1.2522 -1.0367 -1.1721 0.1191
6 0.0158 -1.0541 -1.1710 -0.8799 -0.9787 -0.9763 -1.0172 -0.9620 -1.3164 0.1496
22q11DS Tuple1 
Not-Deleted
1 0.0670 -0.1259 0.0717 -0.1508 0.2653 -0.0241 -0.1144 -0.1205 0.0881 0.0140
2 -0.0325 -0.0797 -0.1033 -0.1055 0.1414 -0.0507 -0.1921 -0.1158 -0.0905 -0.0667
3 -0.1568 -0.0003 0.1309 -0.1154 0.1521 -0.0615 -0.0400 0.1025 0.1660 -0.3315
4 -0.0737 -0.1425 0.0046 0.0205 0.2222 -0.0246 -0.1283 0.1719 0.1093 0.0759
5 0.1166 0.0283 -0.0596 0.1068 0.1951 -0.0478 -0.1887 0.1936 0.0282 0.1191
6 -0.0508 0.1578 0.0755 0.0324 0.1366 -0.0066 0.0569 0.1882 0.0900 0.1496
22q11 Duplication Sample -0.0124 1.1855 0.9201 0.9303 1.0121 0.9377 1.0648 0.9637 1.0250 -0.1863BMC Genomics 2005, 6:180 http://www.biomedcentral.com/1471-2164/6/180
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(∆KCt) for each of the markers from the 22q11.2 region,
using a formula described by Sijben et al. (2003) [42]. In
the context of 22q11DS this approach calculates a ratio;
by comparing the Ct value obtained for each primer pair
between the normal (control) DNA samples and the
patient (affected) DNA samples. This value is then trans-
lated into fold changes (copy number gain or loss) per
sample. For all calculations please refer to the Methods
section.
qPCR data
A summary of the qPCR results is presented in Table 2;
light grey shading denotes loss, whilst dark grey shading
denotes gain. We obtained ∆KCt values of either 0 ± 0.35
indicating an equal ratio of the target and reference, which
corresponds to no loss and therefore no genetic abnor-
mality, or -1 ± 0.35, indicating loss of one copy (microde-
letion), for the affected samples. For the trisomy 22
patient we obtained a ratio of 1 ± 0.35, indicating gain of
one copy. Each experiment was performed in triplicate,
with replicates performed on different days. The inter-
assay (same assay repeated on different days) Ct variation
and the intra-assay Ct variation (the triplicates) was less
than or equal to ± 0.35 cycles.
Discussion
In our analysis we have used a series of 12 qPCR primer
sets to analyze twelve patients with clinical symptoms of
22q11DS and four controls. Ten of the primer sets (test
primers) amplify markers localized within and around the
chromosome 22q11.2-deleted region (D22S181,
PRODH, TUPLE1, COMT, ZNF74, PIK4CA, LZTR1, CAT4,
D22S936 and VPREB1) and two amplify "housekeeping"
genes/markers (reference primers) (G6PDH and HEM3).
The 22q11DS locus contains approximately 50 genes or
pseudogenes and is characterized by an unusual genomic
architecture comprising a large polymorphic chromo-
some-specific low copy repeats (Figure 1)[34]. The repeti-
tive nature of this region of the genome is thought to
increase the frequency of deletions and duplication events
associated with clinical disease. The repetitive nature of
the region of 22q11.2 under study required bioinformat-
ics to identify unique regions for primer design.
In the context of 22q11DS we were trying to discriminate
between 2 copies of a product (normal) versus 1 copy of
the same product (deleted). In order to do this we had to
implement data correction [41] to control for variations
such as the input DNA concentration or reaction efficien-
cies [39]. To perform the correction we used the reference
genes. The copy number of the reference genes will be the
same in all of the samples under investigation. Any varia-
tion in copy number for the reference between samples
will be the result of differences in initial template concen-
tration, as long as the same DNA is sampled for both the
control and target primers. Once the Ct values for the ref-
erence were determined for each sample, it was then pos-
sible to use these to correct the values of the test markers
for variation in initial template concentration. This correc-
tion permitted determination of copy number differences
between the samples under investigation.
Individuals who had previously shown a deletion of
TUPLE1 by FISH also showed deletion by qPCR (group
1). Our data demonstrates that the ∆KCt values, -1 ± 0.35,
for the primers PRODH, TUPLE1, COMT, ZNF74,
PIK4CA, LZTR1, CAT4 and D22S936 are indicative of
deletion (Table 2). A finding that is in 100% concordance
with the FISH results for the TUPLE1 probe. The region of
deletion spanning PRODH, to D22S936, represents an
interval of 2,502,410 base pairs (bp). Furthermore, the
implementation of qPCR has allowed for the identifica-
tion of breakpoint within the 22q11.2 region. The mark-
ers D22S181 and VPREB1 show values indicative of no
deletion (0 ± 0.35), suggesting that the proximal deletion
breakpoint occurs between the markers D22S181 and
PRODH and the distal breakpoint between D22S936 and
VPREB1 (see Table 2 and Figure 1).
Table 3: Example of uncorrected Ct values characteristic to the 
reference (housekeeping) primer G6PDH. Exemplification of the 
uncorrected Ct (average of three replicates) values characteristic 
to the reference (housekeeping) primer G6PDH of the DNA 
samples under study. Although starting concentration of DNA 
for all samples was 10 ng the Ct values for the housekeeping 
genes differed slightly from patient to patient and from group to 
group.
Samples G6PDH Ct value
Control 1 21.2196
2 21.1595
3 23.0891
4 21.3748
Group 1 1 19.8799
2 21.2899
3 20.5799
4 20.7859
5 21.4781
6 19.5612
Group 2 1 20.3756
2 21.1237
3 21.1544
4 21.1484
5 20.5768
6 19.9122
22qDuplication 1 21.3409BMC Genomics 2005, 6:180 http://www.biomedcentral.com/1471-2164/6/180
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The individuals that did not demonstrate loss using the
TUPLE1 FISH probe were also deletion negative by qPCR,
showing ∆KCt values similar to the normal controls (0 ±
0.35) thus indicative of no loss. For the 22q11 trisomy
sample the qPCR results showed ∆KCt values indicative of
duplication (1 ± 0.35) for PRODH, TUPLE1, COMT,
ZNF74, PIK4CA, LZTR1, CAT4 and D22S936. The mark-
ers D22S181 and VPREB1 again showed values indicative
of no copy number change (0 ± 0.35).
To accurately calculate fold changes, to the high precision
required for genomic DNA quantitation, the real-time
data analysis used here makes the most of the existing
methods. The slope values determined from the standard
curve allows for correction for variations in the primers
efficiency and reaction kinetics, whilst the relative abun-
dance ratio, calculated after the samples are normalized
using the reference genes, allows for determination of
gene/marker copy number. This rationale reduces, as
much as possible, the unavoidable approximations intro-
duced with any method of data interpretation.
The use of qPCR to detect and refine copy number differ-
ences in patients suffering from 22q11DS provides a fur-
ther novel application for qPCR methodology. When used
in a research setting, this type of analysis has proven to be
very useful when comparing levels of a transcript or
genomic markers [43,44] between different groups, and
has been widely used in the study of human malignancies.
However, such an approach has rarely been applied in a
clinical setting to study constitutional deletions. The
advantage of this technique over standard FISH assays is
that qPCR provides a quantitative measurement of DNA
copy number.
Conclusion
Here we demonstrate the application of a robust, fast and
accurate real-time quantitative PCR based assay using
SYBR ® Green I dye, that is capable of screening for copy-
number alterations in genomic DNA.
Although qPCR detection methods have previously been
used in 22q11.2 deletion analysis [45-47], these reports
have only used a small number of primers/markers and
have not been able to refine the region of deletion as has
been done here. The utility of the approach outlined in
this paper is the ease with which one can increase resolu-
tion by increasing the number of primers in the 22q11
deleted region thus facilitating accurate mapping of dele-
tion breakpoints. The fine structure of qPCR mapping of
deletions will reveal important clues into the mechanism
by which the deletion occurs and thus will offer insights
into the "at risk" factors predictive of deletions or other
rearrangements.
The implementation of qPCR for genomic copy number
profiling will provide a valuable tool for detection of atyp-
ical microdeletions and/or microduplications in individ-
uals who go undiagnosed by the current available FISH
methods. Such data will be useful for phenotype correla-
tion studies. In addition, this methodology has the advan-
tage of providing greater flexibility and adaptability than
the currently available cytogenetic methods and will be
beneficial in molecular classification and diagnosis.
Methods
Primer design
Primers (Table 1) were designed using Primer Express v2.0
(Applied Biosystems). The parameters for primer design
were as follows; amplicons of 100–250 bp with a penalty
score no higher than 10–12; primer melting temperature
(Tm) range 58°C to 60°C; primer length range 18 to 25
bp, optimal 20 bp; primer G/C content range 20% to
60%; amplicon maximum Tm of 85°C. Runs of more than
three identical nucleotides were avoided as polyG or
polyC stretches can promote non-specific annealing,
whilst runs of polyA and polyT can potentially open up
stretches of the primer-template complex. Primers were
required to be free of self-complementary sequence in
order to avoid hairpin loop formation. In addition, no
more than two G and/or C bases were permitted in the last
five nucleotides at the 3' end to avoid GC clamp forma-
tion. Minimal deviation from the parameters was allowed
only when there were no other options due to the com-
plex nature of the 22q11.2 sequence. Primer and ampli-
con sequences were compared to the human genome
using the BLAT program to guarantee that they showed
100% homology to only the sequence from which they
were designed and also to guarantee that the forward and
reverse primers were free of single nucleotide polymor-
phisms.
Isolation of DNA
The DNA used in this study was obtained from the lym-
phocytes of four normal controls and 12 patients display-
ing clinical features of 22q11DS using phenol-chloroform
extraction [48]. DNA was quality tested. Suitable sample
for the qPCR reactions were of high molecular weight (un-
sheared band of undigested DNA visible on a 0.5% agar-
ose gel) and as clean as possible (an OD 260/280 ranging
from 1.8 to 2.0).
Reaction conditions
Reactions were performed using SYBR Green I PCR Master
Mix (Applied Biosystems), which includes the internal ref-
erence (ROX). Each qPCR reaction comprised 12.5 µl 2×
SYBR Green PCR Master Mix, forward and reverse primer
at optimized concentrations of 800 nM (final concentra-
tion) for the 22q11.2 test primers and 400 nM (final con-
centration) for the reference primers, 10 ng/µl genomicBMC Genomics 2005, 6:180 http://www.biomedcentral.com/1471-2164/6/180
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DNA template and sterile water up to a final volume of 25
µl. The qPCR reactions were performed using the ABI
Prism 7900 high-throughput sequence detection system.
The reaction profile was: initial step, 50°C for 2 min,
denaturation, 95°C for 10 min, then 40 cycles of denatur-
ing at 95°C for 15 sec and combined annealing and exten-
sion at 60°C for 60 sec.
Generating the standard curve
To generate standard curves for the selected primers and
the reference primers a log10 dilution series of genomic
DNA was prepared at concentrations ranging from 102 nM
to 10-2 nM. Each dilution was tested in triplicate. When
analyzed by qPCR, the dilution series produced a set of
standard curves, which were used to calculate the slope
value with the aid of the SDS software version 2.1 Applied
Biosystems (values are shown in Table 1). See Additional
File 3, Figure 2 e. and f. for an example of SDS output
report of standard and amplification plots.
DNA quantification data analysis
Each qPCR experiment contained triplicates of the no-
template-controls and patient samples for all of the prim-
ers tested. On the same reaction plate all DNA samples
were tested with the test and reference primers. When any
particular sample was being tested, the qPCR using refer-
ence primers and that sample were always included on the
reaction plate. Each experiment was performed in tripli-
cate, with replicates being performed on different days.
Quantification was based on the increased fluorescence,
which was measured and recorded using the ABI Prism
7900 sequence detection system and associated SDS soft-
ware version 2.1 (Applied Biosystems). Results were
expressed in terms of the threshold cycle value (Ct; the
cycle at which the change in fluorescence for the SYBR dye
passes a significance threshold). The threshold values are
shown in Table 1. The output of the results was exported
in tab-delimited text file format. Further calculations were
performed using Microsoft Excel. PCR products were
resolved by agarose gel electrophoresis to confirm the
presence of a single band of the expected size (See Addi-
tional File 3, Figure 2 a. showing SDS output of amplifica-
tion plot for 14 DNA samples for the PRODH and
G6PDH primer sets along with images of corresponding
gel bands c. and d.).
Data normalization
The qPCR data was normalized adapting a method
devised by Moody et al. (2000) [41] and also described by
Sijben et al. (2003) [42]. (See Additional File 1: Deriva-
tion of the formula)
Where:
KCti = 'Corrected Ct' (KCt) of the test primer (T) against the
reference (R)
ACtR = the Average Ct value for Reference primer set for all
the samples included in one qPCR run (control and
patient).
CtRi = Ct value for Reference primer set for the sample to
be corrected.
SR = slope value (from the standard curve) for reference
primer set.
ST = slope value (from the standard curve) for test primer
set.
CtTi = Ct value for test primer set.
Copy number calculation
Fold copy number (∆KCt) change for each of the markers
from the 22q11.2 region, was obtained using the formula:
∆KCt = KCt/control - KCt/affected
∆KCt = fold change (copy number gain or loss)
KCt/control = "Corrected Ct" of the test primer for the con-
trol samples.
KCt/affected  = "Corrected Ct" of the test primer for the
affected sample.
(Of note when multiple controls were used in the same
reaction run the KCt/control was obtained by averaging all
the controls'
"Corrected Ct" – KCt/control's). (See Additional File 2:
Working example)
Abbreviations
qPCR – Real time Quantitative Polymerase Chain Reac-
tion
G6PDH – Glucose-6-Phosphate Dehydrogenase
Reference (R) – refers to the sequence we use to standard-
ize against – the sequence, which we expect to remain
unchanged in all the DNA samples (patient and control),
and is the equivalent of the housekeeping gene use in
expression studies. In our experiments we use G6PDH
and HEM3.
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Target (T) – refers to the sequence originating from the
region of interest which we test and which we expect to
find modifications (deletion or duplication).
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